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Introduction
It was a mystery that acetylcholine (ACh) can contract 
all smooth muscles of the body except those of the blood 
vessels. It was not until 1980 when Furchgott and Zawadzki 
discovered that the relaxation of blood vessels by ACh 
requires the presence of endothelial cells, and that ACh, 
acting on muscarinic receptors of these cells, stimulates the 
release of substance(s) that cause relaxation of the vascular 
smooth muscle.[1] Furchgott named these substances as the 
endothelium-derived relaxing factor(s), which was proposed 
by Furchgott and Ignarro independently in 1986 to be nitric 
oxide (NO).[2] NO was found to mediate its biological effects 
by activating guanylyl cyclase (GC) and increasing cyclic 
guanosine monophosphate (cGMP) synthesis which, in 
turn, activates certain proteins resulting in different actions 
including smooth muscle relaxation, cardiac protection, 
neuronal plasticity, endothelial permeability, and gene 
transcription. cGMP actions were found to be terminated by 
phosphodiesterase enzyme 5 (PDE-5).[3] Although nonselective 
PDE inhibitors (such as theophylline) have been in the 
therapeutic use for over 80 years, many important selective 
PDE-5 inhibitors have been introduced for the treatment of a 
wide range of diseases in the past 10 years. This review is an 
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attempt to discuss the pharmacological basis of the NO-cGMP 
system and briefly describes the clinical applications of drugs 
that inhibit PDE-5.
Literature Search
Literature search of the electronic sources of different databases 
such as PubMed Central, Google Scholar, and Scopus were 
used. Keywords used for search include but not limited to 
cyclic guanosine monophosphate (mechanisms and functions), 
erectile dysfunctions (EDs) (drugs used), nitric oxide, and 
phosphodiesterase enzyme 5 inhibitors (clinical applications). 
One hundred and sixty‑five articles were studied, out of which 
45 articles were referred to in this review.
Physiology and the Pathophysiology 
of the Nitric Oxide‑Cyclic Guanosine 
Monophosphate System
NO is synthesized by the oxidation of L-arginine catalyzed 
by NO synthases (NOSs) that utilizes NADPH and O2 as 
substrates[4] [Figure 1]. Three isoforms of NOS have been 
discovered: Neuronal NOS (nNOS or NOS 1), inducible 
NOS (iNOS or NOS 2), and finally endothelial NOS (eNOS 
or NOS 3).[4]
NO mediates its biological effects by activating GC and 
increasing cGMP synthesis from guanosine triphosphate 
(GTP) [Figure 1]. There are two forms of GC, soluble GC and 
membrane-bound particulate GCs.[5] The formed cGMP activates 
certain cGMP-dependent protein kinase (cGK), which, in turn, 
activates certain proteins resulting in different actions including 
smooth muscle relaxation, cardiac protection, neuronal plasticity, 
endothelial permeability, and gene transcription.[5]
The cGMP generated by GC is hydrolyzed by the members of 
the cyclic nucleotide PDEs, a group of enzymes that control the 
rate of hydrolysis of cyclic adenosine monophosphate (cAMP) 
and cGMP. Eleven different PDE families (PDE 1–11) 
have been described,[6] some PDEs are selective for the 
hydrolysis of cAMP (PDE 4, 7, and 8) or cGMP (PDE 5, 6, 
and 9). Others can hydrolyze both cAMP and cGMP (PDE 
1, 2, 3, 10, and 11).[6] Defects in the PDEs functions had 
been implicated in many pathological conditions including 
inflammations, cardiovascular diseases, neurodegeneration, 
and cancer.[7] On the other hand, selective PDEs inhibitors were 
developed for the treatment of different diseases including ED, 
respiratory diseases, and benign prostatic hypertrophy (vide 
infra). The following will provide a brief description of 
the most important pharmacological effects related to the 
therapeutic uses of NO-cGMP system.
Relaxation of vascular smooth muscle
cGMP is a powerful vasodilator with a short half-life of a few 
seconds. The formed cGK causes a decrease in intracellular 
calcium, which ensures that myosin light chain kinase can no 
longer phosphorylate myosin molecule and thereby stopping 
the cross-bridge cycle leading to the relaxation of the smooth 
muscles of the blood vessels [Figure 1].[7] The decrease of 
intracellular calcium can be achieved by different mechanisms, 
including but not limited to, (a) an increase in the open 
probability of large-conductance Ca++-activated K+ channels, 
resulting in hyperpolarization of the membrane and closing 
of voltage-dependent Ca++ channels thereby reducing Ca++ 
influx or (b) alternatively an activation of the sarcoplasmic/
endoplasmic reticulum Ca++-ATPase, promoting Ca++ reuptake 
into the sarcoplasmic/endoplasmic reticulum, decreasing 
intracellular calcium.[7]
Because of its powerful vasodilatory effect, NO has been 
suggested to be one of the most important metabolic modulators 
of blood pressure (BP), tonically restraining BP by at least 
30 mmHg in healthy young adults.[8] Genetically engineered 
Figure 1: (a) In the endothelial cell, nitric oxide is produced from L‑arginine by the enzymatic action of nitric oxide synthase. (b) In the cell, nitric oxide 
will activate soluble guanylyl cyclase converting guanosine triphosphate to cyclic guanosine monophosphate. Cyclic guanosine monophosphate 
will activate cyclic guanosine monophosphate‑dependent protein kinase, which leads to a decrease in intracellular calcium (Ca++)I (see text for 
details). The actions of cyclic guanosine monophosphate are terminated by hydrolysis by phosphodiesterase enzyme 5
a
b
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mice with deletion of the eNOS gene have been found to 
have an increased arterial BP, illustrating a role of NO in the 
control of the cardiovascular homeostasis.[9] Furthermore, it 
was shown that other kinases may affect the activity of eNOS, 
where the endothelial cells of endothelium‑specific liver 
kinase B1 (LKB1) knockout (LKB1endo−/−) mice exhibited 
reduced eNOS activity and AMP kinase (a downstream 
enzyme of LKB1) compared with wild-type cells. These 
knockout (LKB1endo−/−) mice exhibited hypertension, cardiac 
hypertrophy, and impaired endothelium-dependent relaxation. 
These findings indicate that LKB1 regulates eNOS activity 
affecting endothelial function and BP.[10]
Moreover, the vasodilating effect of NO is the main vasoactive 
NANC (nonadrenergic and noncholinergic) mediator of penile 
erection through the relaxation of corpus cavernosum smooth 
muscle.[11] Impaired NO bioactivity is believed to be one of the 
major pathogenic mechanisms of ED (vide infra).
Cardiac functions
Mammalian myocardium has been found to express both 
eNOS and nNOS.[12] eNOS-derived NO via cGMP-dependent 
signaling has been reported to increase the left ventricular (LV) 
compliance, attenuate beta-adrenergic inotropy and enhance 
parasympathetic/muscarinic responses, and mediate the 
negative inotropic response to β3 adrenoreceptor stimulation.
[12] 
Moreover, NOS has the ability to alter intracellular Ca++ 
handling and the myofilament response to Ca++, thereby 
impacting the systolic and diastolic performance of the 
myocardium.[13] Findings from experiments using NO 
donors and NOS inhibition or gene deletion clearly implicate 
dysfunctional NOS as a critical contributor to many 
cardiovascular disease states including heart failure, diabetic 
cardiomyopathy, ischemia/reperfusion injury, and atrial 
fibrillation.[13] On the other hand, high output iNOS isoform 
may also be expressed in pathological conditions.[14] The 
regulation of the cardiac functions by endogenous NO has 
been suggested to be dependent on the distinct subcellular 
locations of nNOS and eNOS, through vascular-dependent 
and vascular-independent effects.[14]
Moreover, several reports have provided experimental 
evidences that cGMP degradation by PDE-5 has functional 
importance in cardiomyocytes, especially when they 
are exposed to overload and oxidative stress. In animal 
models, pressure overload resulted in increased myocardial 
PDE-5 levels, where superoxide dismutase blunted the 
increase in PDE-5 and protected against LV hypertrophy 
and congestive heart failure, suggesting that oxidative 
stress increases PDE-5 expression leading to hypertrophy.
[15] Furthermore, stimulation of myocyte hypertrophy by 
phenylephrine was blunted by PDE-5 gene silencing in 
a PKG‑dependent manner. These data confirm the role 
of PDE-5 in cardiomyocyte hypertrophy modulation.[16] 
Similar results were reported in humans where ventricular 
PDE-5 expression was increased in patients with advanced 
heart failure.[17] These results led to a tremendous interest in 
identifying new clinical uses of PDE-5 inhibitors in various 
ailments of cardiovascular diseases.
Blood platelets aggregation
The platelet anti-aggregatory effects of cAMP and cGMP are 
well documented. In experiments published in 1990, Radomski 
et al.[18] have shown that human platelets contain NOS, which 
was activated when platelets were stimulated. The consequent 
generation of NO modulated platelet reactivity by increasing 
cGMP, which led to the phosphorylation of substrate proteins 
by PKGI, preventing platelet aggregation.[18] Radomski 
et al. suggested that the activity of this pathway in platelets 
plays an important physiological, pathophysiological, and 
therapeutic significance. On the other hand, prostacyclin 
produced its anti-aggregatory effect through the formation of 
cAMP which phosphorylated substrate proteins by PKA.[19] 
PKA and PKGI phosphorylate, a broad panel of substrate 
proteins, will result in the inactivation of small G-proteins 
of the Ras and Rho families, inhibition of the release of Ca++ 
from intracellular stores, and modulation of actin cytoskeleton 
dynamics.[19] This anti-thrombotic effect is believed to be one 
of the vascular-dependent effects of NO in regulating and 
protecting cardiac functions.[14] Moreover, defects in platelet 
cyclic nucleotide signaling have been suggested to play a 
role in common diseases such as ischemic heart disease, 
heart failure, and diabetes, where reduced sensitivity of 
platelets to the inhibitory effects of NO contributes to platelet 
hyper-reactivity.[20]
Approved Clinical Applications of PDE‑5 
Inhibitors
Despite the many advances that have been made in the basic 
biological sciences in the past four decades, few new innovated 
groups of drugs have been introduced into the medical practice. 
One of these groups is selective PDE inhibitors. Although 
nonselective PDE inhibitors (such as theophylline) have 
been in the therapeutic use for over 80 years, many important 
selective PDE-5 inhibitors have been introduced for the 
treatment of a wide range of diseases in the past 10 years.
The first selective PDE‑5 inhibitor introduced in the early 80s 
of the last century was zaprinast, which was proved to have 
moderate bronchodilator effects in exercise-induced asthma.[21] 
Later, zaprinast was shown to produce relaxation of the smooth 
muscles of the rat aorta and to enhance NO-induced relaxation 
of isolated corpus cavernosum.[22] This initiated a rapid 
progress in the development of selective PDE-5 inhibitors that 
culminated in the discovery of sildenafil, which was introduced 
initially for the treatment of angina pectoris and proved later 
to be effective in the treatment of several clinical conditions. 
The following are descriptions of the approved clinical uses 
of PDE-5 inhibitors.
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Erectile dysfunctions
Ignarro et al .  in 1990 reported that NO (through 
cGMP-dependent action) is responsible for the relaxation of 
rabbit corpus cavernosum smooth muscle induced by electrical 
field stimulation and proposed that NO production could 
potentially mediate penile erection.[23] The same relaxation 
under the same condition was reported in human corpus 
cavernosum.[24] Later, many researches had identified NO 
as the primary biochemical mediating erectile function, and 
impairment of NO release or action is a major pathogenic 
mechanism of organic ED.[25] ED is defined as the consistent 
inability to attain or maintain a penile erection of sufficient 
quality to permit satisfactory sexual intercourse.[25] The penile 
erection reported as a side effect of sildenafil during its phase 
I clinical trial for the treatment of angina had led to the 
proposal that PDE-5 inhibitors may be useful to treat ED.[26] 
After several clinical trials, sildenafil was the first PDE‑5 
inhibitors approved in 1998 by the American Food and Drug 
Administration (FDA) for the treatment of EDs. Sildenafil 
became a wonder drug for millions of patients and because of 
the huge market demand, many new PDE-5 inhibitors were 
introduced including tadalafil, vardenafil, udenafil, avanafil, 
and mirodenafil.
All PDE-5 inhibitors are equally effective and safe for the 
treatment of ED; however, they differ in their side effects, 
potency, and duration of action. Sildenafil‑induced blue vision 
changes were reported to be due to the inhibition of PDE-6 
in the retina. Tadalafil, on the other hand, is far less active 
against PDE‑6 isoenzyme than either sildenafil or vardenafil.[27] 
In terms of potency, tadalafil was reported to be the most 
effective agent, followed by vardenafil and most preferred by 
patients and physicians.[28] The preference of patients and their 
physicians to tadalafil might have to do with its long duration 
of action (half‑life time 17.5 h compared to 4 h for sildenafil) 
which allows the patient more freely to choose the timing and 
setting of the sexual intercourse.
The efficacy of PDE‑5 inhibitors therapy, based on measures 
of the International Index of Erectile Function (IIEF) 
compared with placebo, ranges from 65% to 75% for 
successful intercourse and from 80% to 85% for significantly 
improved erections.[29] This efficacy has been demonstrated 
in a broad population, including men with hypertension, 
diabetes mellitus, postradical prostatectomy; psychogenic, 
organic, or mixed causes of ED, and those with mild-to-severe 
ED.[29]
PDE-5 inhibitors are prescribed either as “on-demand” 
dosing taken an hour before sexual intercourse or continuous 
“once-daily” dosing. The on-demand PDE-5 inhibitors were 
reported to be inadequate to restore a “normal” sexual life in 
40–50% of the patients with ED. On the other hand, outcomes 
generally improved with repeated daily dosing, especially in 
the group of patients that initially do not respond.[30]
Side effects of PDE-5 inhibitors include headache, dyspepsia, 
back pain, myalgia (muscle aches), flushing, and stuffy or 
runny nose. These side effects are usually mild in nature 
and the discontinuation rate because of these side effects 
are always low.[30] However, contraindications for the use of 
PDE-5 inhibitors include history of unstable angina pectoris 
or myocardial infarction, some arrhythmias, and poorly 
controlled hypertension.[31] The concomitant use of PDE-5 
inhibitors with nitrites and nitrates is contraindicated because 
of the severe hypotension that results from the combination.[31] 
PDE-5 inhibitors should not be given in combination with 
other drugs which inhibit or induce the liver enzyme CYP3A4, 
including HIV protease inhibitors, ketoconazole, itraconazole, 
erythromycin, and grapefruit juice because of the potential 
pharmacokinetic interactions.[32] Concurrent administration 
of sildenafil and warfarin may increase the risk of bleeding. 
Drugs prolonging QTc interval should never be administered 
together with vardenafil for the potential risk of further increase 
in QTc.[33]
In summary, the discovery of long-acting PDE-5 inhibitors 
such as tadalafil and the daily dose regimen has undoubtedly 
proven to be highly effective in the management of ED from 
a variety of causes.
Benign prostatic hyperplasia
Benign prostatic hyperplasia (BPH) involves hyperplasia of 
prostatic stromal and epithelial cells that may partially or 
completely obstruct urine flow through the urethra. Clinically, 
BPH leads to voiding dysfunction, which is most often referred 
to as lower urinary tract symptoms (LUTSs). Men who 
present with symptomatic BPH and LUTS are at an increased 
risk for sexual dysfunction, including ED and ejaculatory 
dysfunction.[34]
The main groups that are used for the treatment of LUTS 
associated with BPH are α1 adrenergic receptor antagonists 
(e.g., tamsulosin), 5-alpha reductase inhibitor (5-alphaRIs, 
e.g., dutasteride), and anti-muscarinic agents (e.g., tolterodine), 
either alone or in combination.[35] However, the use of α1 
blockers and/or 5-alphaRIs has been associated with sexual 
dysfunctions and ejaculatory disorders,[36] which may worsen 
any sexual dysfunction that might be caused by BPH and 
LUTS.
Several clinical studies have assessed PDE-5 inhibitors 
including vardenafil, sildenafil, and tadalafil in reducing LUTS; 
however, tadalafil is the only PDE‑5 inhibitor approved by the 
FDA in 2011 for the treatment of signs and symptoms of BPH, 
as well as in men with both ED and signs and symptoms of 
BPH.[37] In this context, 12-week treatment with once daily 
5 mg tadalafil had demonstrated significant improvements 
in the total International Prostate Symptom Score (IPSS), 
BPH impact index, and IIEF. These improvements took place 
regardless of the age, previous treatment with α1 adrenergic 
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blocker, BPH-LUTS severity at baseline, or ED status.[37] Using 
integrated data analyses from four placebo-controlled clinical 
studies, Brock et al.[38] have shown that tadalafil‑induced 
improvement for LUTS is independent of improvements in 
ED; where the unidirectional path analysis model suggested 
that 70% of the total IPSS score improvement was derived 
from a direct treatment effect, while 30% of the total IPSS 
score was an indirect treatment effect via IIEF improvement. 
This supports the suggestion of dual mechanisms of actions 
of tadalafil on LUTSs/BPH, and EDs.
Combination therapy has also been tried using PDE-5 
inhibitors and α1 blockers or 5-alphaRIs. A systematic review 
and meta-analysis of seven publications involving 515 patients 
showed that the combined use of PDE-5 inhibitors and α1 
blockers resulted in additive favorable effects in men with 
ED and LUTS compared with PDE-5 inhibitor monotherapy, 
suggesting that alpha‑blockers may enhance the efficacy of 
PDE‑5 inhibitors, which is beneficial for the treatment of ED 
and LUTS.[39] Similar results were obtained when tadalafil 
was co‑administered with the 5‑alphaRI (finasteride), where 
the results obtained from an international, randomized, 
double-blind parallel study showed that the co-administration 
of tadalafil/finasteride provided early improvement in LUTSs 
in men with BPH and prostatic enlargement. Tadalafil/
finasteride co‑administration also improved erectile function 
in men who have comorbid ED.[40]
In summary, the combination of PDE-5 inhibitors and α1 
blockers or 5-alphaRI is becoming a standard treatment for the 
management of LUTS associated with BPH and ED.
Pulmonary hypertension
Pulmonary hypertension (PH) is a general term indicating an 
abnormal increase of BP on the right side of the heart. The 
high pressure could be caused by a medical condition such as 
chronic lung disease, blood clots in the blood vessels of the 
lungs (thromboembolism), or LV muscle or valve diseases. 
This type of PH was called “secondary PH,” but is now referred 
to as PH. Pulmonary arterial hypertension (PAH), “used to be 
called primary PH,” occurs due to pathological changes in the 
resistance of pulmonary circulation where the blood vessels in 
the lung become thick and narrow, resisting blood flow.[41] The 
exposure of the right ventricle to pressure overload by chronic 
PH from any cause will result in an initial adaptive response 
of myocardial hypertrophy, which is followed by progressive 
contractile dysfunction and consequently heart failure.[41]
Three classes of drugs have been developed and approved for 
the treatment of PAH: Prostanoids (prostacyclin or prostacyclin 
analogues), endothelin-1 receptor antagonists (ERAs, 
e.g., bosentan, sitaxsentan, and ambrisentan), and PDE-5 
inhibitors (sildenafil and tadalafil). All the three classes of 
medications have been shown to favorably affect hemodynamic 
parameters as well as to improve functional capacity and 
exercise tolerance.[42]
In 16-weeks, double-blind, placebo-controlled study of 
405 patients, 40 mg tadalafil once daily was well tolerated and 
provided the best results in terms of improved exercise capacity 
and quality of life measures and reduced clinical worsening.[43] 
Sildenafil produced similar results. Moreover, the addition 
of sildenafil to the therapy of neonates with advanced PAH 
progression during bosentan monotherapy was associated 
with a significant improvement of WHO functional class and 
improved exercise capacity.[44]
When the long-term outcomes were assessed in a meta-analysis 
of 24 articles with 3758 patients, it was found that only 
intravenous prostacyclin has a proven survival benefit, 
particularly in patients with severe disease. PDE-5 inhibitors 
did not improve mortality. However, there are several 
limitations to this study including a relatively small sample 
size and short-time follow-up.[45]
Thus, irrespective of the proved efficacy of PDE‑5 inhibitors 
in improving hemodynamic parameters as well as functional 
capacity and exercise tolerance in PAH, the long-term mortality 
and duration of survival improvement are uncertain and require 
further research.
Conclusion
The discovery of the mechanisms responsible for NO actions 
provided the humanity with many clues for understanding 
normal physiological functions and the treatment of many 
diseases. There is no doubt that the discovery of PDE-5 
inhibitors is a milestone in innovation and drug discovery. The 
list of the medical indications of this group is expanding and we 
would expect greater advances in this respect. The discovery 
of long‑acting PDE‑5 inhibitors such as tadalafil and the daily 
dose regimen has undoubtedly proven to be highly effective 
in the management of ED from a variety of causes. The use 
of PDE-5 inhibitors seems to provide better choice for the 
treatment of BPH as other drugs used for this condition such as 
α1 blockers and/or 5-alphaRIs have been associated with sexual 
dysfunctions and ejaculatory disorders. However, the combined 
use of PDE-5 inhibitors and α1 blockers resulted in additive 
favorable effects compared with PDE-5 inhibitors monotherapy. 
Irrespective of the proved efficacy of PDE‑5 inhibitors in 
improving hemodynamic parameters as well as functional 
capacity and exercise tolerance in PAH, the long-term mortality 
and duration of survival improvement are uncertain and require 
further research. Theoretically, PDE-5 inhibitors would provide 
many beneficial effects through their anti‑hypertrophic effect 
on cardiac muscles and anti-thrombotic effect, thus protecting 
cardiac functions. However, many clinical trials are underway 
evaluating the effectiveness of PDE inhibitors in different sets 
of cardiac diseases.
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